Title |
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
|
---|---|
Published in |
Drugs, August 2018
|
DOI | 10.1007/s40265-018-0965-8 |
Pubmed ID | |
Authors |
Nicola Tarantino, Francesco Santoro, Michele Correale, Luisa De Gennaro, Silvio Romano, Matteo Di Biase, Natale Daniele Brunetti |
Abstract |
Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives. In the lack of successful results from the main cardiovascular trials, guidelines recommend the use of peroxisome proliferator-activated receptor agonists in selected cases, i.e. patients with true atherogenic dyslipidemia. However, recent observations indicate that fenofibrate treatment may provide a reliable complementary support against residual cardiovascular risk. We therefore summarize current evidence on fenofibrate, seeking to provide an updated interpretation of recent studies in the field. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 18% |
Student > Master | 3 | 18% |
Student > Doctoral Student | 2 | 12% |
Researcher | 2 | 12% |
Student > Ph. D. Student | 1 | 6% |
Other | 1 | 6% |
Unknown | 5 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 3 | 18% |
Medicine and Dentistry | 3 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 12% |
Mathematics | 1 | 6% |
Social Sciences | 1 | 6% |
Other | 1 | 6% |
Unknown | 6 | 35% |